A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis (PRESIDIO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04033926 |
Recruitment Status :
Recruiting
First Posted : July 26, 2019
Last Update Posted : November 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
"This is a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of treatment with KZR-616 in patients with active Polymyositis (PM) or Dermatomyositis (DM). Patients will be evaluated for eligibility during the Screening Period. Eligible patients will be randomized 1:1 to Arm A or Arm B of the study.
During the 32-week treatment period, patients will receive study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each.
This study will be conducted on an outpatient basis.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Polymyositis Dermatomyositis | Drug: KZR-616 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis |
Actual Study Start Date : | January 14, 2020 |
Estimated Primary Completion Date : | February 2022 |
Estimated Study Completion Date : | April 2022 |

Arm | Intervention/treatment |
---|---|
Arm A
|
Drug: KZR-616
Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks Drug: Placebo Subcutaneous injection for 16 weeks |
Arm B
|
Drug: KZR-616
Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks Drug: Placebo Subcutaneous injection for 16 weeks |
- Primary Outcome Measure [ Time Frame: From start to end of KZR-616 treatment for both sequence arms combined. ]Mean change from start to end of KZR-616 treatment in the Total Improvement Score (TIS), which ranges from 0 to 100.
- Proportion of patients with an increase ≥20 points on the TIS from start to end of KZR-616 treatment. [ Time Frame: 16 weeks ]
- Proportion of patients from start to end of KZR-616 treatment meeting International Myositis Assessment and Clinical Studies Group (IMACS) Definition of Improvement (DOI). [ Time Frame: 16 weeks ]
- Absolute change from start to end of KZR-616 treatment in the IMACS individual core set activity measures (CSAMs) [ Time Frame: 16 weeks ]
- Percent change from start to end of KZR-616 treatment in the IMACS individual CSAMs [ Time Frame: 16 weeks ]
- For patients with DM, the mean change from start to end of KZR-616 treatment in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) [ Time Frame: 16 weeks ]
- For patients with DM, the mean change from start to end of KZR-616 treatment in the Peak Pruritus Numeric Rating Scale. [ Time Frame: 16 weeks ]The Peak Pruritus Numeric Rating Scale ranges from a score of 0 to 10, with 0 representing no itch and 10 representing the worst itch imaginable during the worst moment within a 24-hour recall period.
- Safety and tolerability of KZR-616 in patients with PM or DM as assessed by monitoring incidence and severity of adverse events (AEs) [ Time Frame: 40 weeks ]
- Peak plasma concentration (Cmax) following KZR-616 injection [ Time Frame: Day 1 ]
- Time to peak plasma concentration (Tmax) following KZR-616 injection [ Time Frame: Day 1 ]
- Area under the plasma concentration versus time curve (AUC) following KZR-616 injection [ Time Frame: Day 1 ]
- Half life (T1/2) following KZR-616 injection [ Time Frame: Day 1 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients at least 18 years of age
- Body Mass Index (BMI) of 18 to 40 kg/m2
- Diagnosis of probable or definite DM or PM
-
Must confirm eligibility unless at least 1 of the following is present:
- Muscle biopsy with evidence of active myositis within the last 6 months prior to or at Screening
- Electromyography or magnetic resonance imaging with evidence of active myositis within the last 6 months prior to Screening
- A creatine kinase (CK) ≥4 × upper limit of normal (ULN).
-
Must have demonstrable muscle weakness as measured by the Manual Muscle Testing-8 muscle Groups (MMT-8) with a score ≥80/150 but ≤136/150 units and any 2 of the following:
- Physician Global Assessment (MDGA) visual analog scale (VAS) ≥2 cm
- Patient Global Assessment of Disease Activity (PtGADA) VAS ≥2 cm
- At least one muscle enzyme laboratory measurement ≥1.3 × ULN
- Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity VAS ≥1 cm.
- Documented inadequate response OR have demonstrated documented toxicity or intolerance to prior standard of care therapies
- Has had age-appropriate cancer screening that is up to date and negative for evidence of malignancy as per local standard of care
Exclusion Criteria:
- Has significant muscle damage or has a muscle damage VAS score ≥5 cm on the MDI
- Any other form of myositis or myopathy other than PM or DM
- Any condition that precludes the ability to quantitate muscle strength
- Has severe interstitial lung disease or has a pulmonary damage VAS score ≥5 cm on the Myositis Damage Index (MDI)
- Presence of autoinflammatory disease
- Use of nonpermitted medications or treatments within the specified washout periods prior to screening
- Patient has had recent serious or ongoing infection, or risk for serious infection
-
Any of the following laboratory values at Screening:
- Estimated glomerular filtration rate <45 mL/min
- Hemoglobin <10 g/dL
- White blood cell (WBC) count <3.0 × 109/L
- Absolute neutrophil count (ANC) <1.5 × 109/L (1500/mm3)
- Platelet count <100 × 109/L
- Serum AST or serum ALT >2.5 × ULN (unless considered consistent with muscle origin)
- Serum alkaline phosphatase >2.5 × ULN
- Total bilirubin >1.5 × ULN (3 × ULN for patients with documented Gilbert's syndrome)
- Thyroid stimulating hormone outside of the central laboratory normal range
- Immunoglobulin G (IgG) <500 mg/dL.
- Presence of New York Heart Association Class III or IV heart failure, or uncontrolled blood pressure, or prolonged QT interval
- Major surgery within 12 weeks before Screening or planned during the study period
- Clinical evidence of significant unstable or uncontrolled diseases
- Any active or suspected malignancy, including myeloproliferative or lymphoproliferative disorder, or history of documented malignancy within the last 5 years before Screening or within 3 years of diagnosis of myositis, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04033926
Contact: Clinical Operations | (650)822-5600 | ClinicalTrials@KezarBio.com |
United States, California | |
KZR Research Site | Recruiting |
Beverly Hills, California, United States, 90211 | |
KZR Research Site | Recruiting |
Orange, California, United States, 92868 | |
United States, Florida | |
KZR Research Site | Recruiting |
Miami, Florida, United States, 33136 | |
United States, Georgia | |
KZR Research Site | Recruiting |
Atlanta, Georgia, United States, 30322 | |
United States, Kansas | |
KZR Research Site | Recruiting |
Kansas City, Kansas, United States, 66160 | |
United States, Maryland | |
KZR Research Site | Recruiting |
Baltimore, Maryland, United States, 21224 | |
United States, Michigan | |
KZR Research Site | Recruiting |
Ann Arbor, Michigan, United States, 48109 | |
United States, New York | |
KZR Research Site | Recruiting |
Great Neck, New York, United States, 11021 | |
United States, Pennsylvania | |
KZR Research Site | Recruiting |
Duncansville, Pennsylvania, United States, 16635 | |
KZR Research Site | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
KZR Research Site | Recruiting |
Austin, Texas, United States, 78756 | |
United States, Virginia | |
KZR Research Site | Not yet recruiting |
Henrico, Virginia, United States, 23233 | |
Czechia | |
KZR Research Site | Not yet recruiting |
Prague, Czechia | |
Germany | |
KZR Research Site | Not yet recruiting |
Göttingen, Germany | |
Poland | |
KZR Research Site | Not yet recruiting |
Bydgoszcz, Poland | |
KZR Research Site | Not yet recruiting |
Elbląg, Poland | |
KZR Research Site | Not yet recruiting |
Kraków, Poland | |
KZR Research Site | Not yet recruiting |
Szczecin, Poland | |
KZR Research Site | Not yet recruiting |
Wrocław, Poland |
Study Director: | Kezar | Kezar Life Sciences, Inc. |
Responsible Party: | Kezar Life Sciences, Inc. |
ClinicalTrials.gov Identifier: | NCT04033926 |
Other Study ID Numbers: |
KZR-616-003 |
First Posted: | July 26, 2019 Key Record Dates |
Last Update Posted: | November 17, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Myositis Idiopathic inflammatory myopathies Polymyositis |
Dermatomyositis Musculoskeletal Diseases Muscular Diseases |
Dermatomyositis Polymyositis Myositis Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Connective Tissue Diseases Skin Diseases |